|
1
|
Sharma J, Bhar S and Devi CS: A review on
interleukins: The Key manipulators in rheumatoid arthritis. Mod
Rheumatol. 27:723–746. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lage-Hansen PR, Lindegaard H, Chrysidis S
and Terslev L: The role of ultrasound in diagnosing rheumatoid
arthritis, what do we know? An updated review. Rheumatol Int.
37:179–187. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tarp S, Furst DE, Dossing A, Østergaard M,
Lorenzen T, Hansen MS, Singh JA, Choy EH, Boers M, Suarez-Almazor
ME, et al: Defining the optimal biological monotherapy in
rheumatoid arthritis: A systematic review and meta-analysis of
randomised trials. Semin Arthritis Rheum. 46:699–708. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jiang M, Ren F, Zheng Y, Yan R, Huang W,
Xia N, Luo L, Zhou J and Tang L: Efficacy and safety of
down-titration versus continuation strategies of biological
disease-modifying anti-rheumatic drugs in patients with rheumatoid
arthritis with low disease activity or in remission: A systematic
review and meta-analysis. Clin Exp Rheumatol. 35:152–160.
2017.PubMed/NCBI
|
|
5
|
Haus E, Sackett-Lundeen L and Smolensky
MH: Rheumatoid arthritis: Circadian rhythms in disease activity,
signs and symptoms, and rationale for chronotherapy with
corticosteroids and other medications. Bull NYU Hosp Jt Dis. 70
(Suppl 1):S3–S10. 2012.
|
|
6
|
Steunebrink LM, Versteeg GA, Vonkeman HE,
Ten Klooster PM, Kuper HH, Zijlstra TR, van Riel PL and van de Laar
MA: Initial combination therapy versus step-up therapy in treatment
to the target of remission in daily clinical practice in early
rheumatoid arthritis patients: Results from the dream registry.
Arthritis Res Ther. 18:602016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bernard NJ: Rheumatoid arthritis: Choline
kinase-more than a cancer therapy target? Nat Rev Rheumatol.
10:6992014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iwata S, Nakayamada S, Fukuyo S, Kubo S,
Yunoue N, Wang SP, Yoshikawa M, Saito K and Tanaka Y: Activation of
syk in peripheral blood B cells in patients with rheumatoid
arthritis: A potential target for abatacept therapy. Arthritis
Rheumatol. 67:63–73. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bernard NJ: Rheumatoid arthritis: Are
FcRL4+ B cells the next target for RA biologic therapy? Nat Rev
Rheumatol. 10:1272014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pincus T and Castrejon I: Evidence that
the strategy is more important than the agent to treat rheumatoid
arthritis. Data from clinical trials of combinations of
non-biologic DMARDs, with protocol-driven intensification of
therapy for tight control or treat-to-target. Bull Hosp Jt Dis. 71
(Suppl 1):S33–S40. 2013.
|
|
11
|
Rabquer BJ and Koch AE: NK4 therapy: A new
approach to target angiogenesis and inflammation in rheumatoid
arthritis. Arthritis Res Ther. 15:1192013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sakai R, Tanaka M, Nanki T, Watanabe K,
Yamazaki H, Koike R, Nagasawa H, Amano K, Saito K, Tanaka Y, et al:
Drug retention rates and relevant risk factors for drug
discontinuation due to adverse events in rheumatoid arthritis
patients receiving anticytokine therapy with different target
molecules. Ann Rheum Dis. 71:1820–1826. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Svanstrom H, Lund M, Melbye M and
Pasternak B: Concomitant use of low-dose methotrexate and NSAIDs
and the risk of serious adverse events among patients with
rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 27:885–893. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Best JH, Kong AM, Lenhart GM, Sarsour K,
Stott-Miller M and Hwang Y: Association between glucocorticoid
exposure and healthcare expenditures for potential
glucocorticoid-related adverse events in patients with rheumatoid
arthritis. J Rheumatol. 45:320–328. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pasi S, Kant R, Gupta S and Surolia A:
Novel multimeric IL-1 receptor antagonist for the treatment of
rheumatoid arthritis. Biomaterials. 42:121–133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang HQ, Liu XG, Yang X, Chen T and Yu SG:
Effect of different types of moxibustion intervention on expression
of inflammatory cytokines IL-1 and TNF-alpha in rabbits with
rheumatoid arthritis. Zhen Ci Yan Jiu. 38:134–139. 2013.(In
Chinese). PubMed/NCBI
|
|
17
|
Adachi M, Okamoto S, Chujyo S, Arakawa T,
Yokoyama M, Yamada K, Hayashi A, Akita K, Takeno M, Itoh S, et al:
Cigarette smoke condensate extracts induce IL-1-beta production
from rheumatoid arthritis patient-derived synoviocytes, but not
osteoarthritis patient-derived synoviocytes, through aryl
hydrocarbon receptor-dependent NF-kappa-B activation and novel
NF-kappa-B sites. J Interferon Cytokine Res. 33:297–307. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alten R, Gram H, Joosten LA, van den Berg
WB, Sieper J, Wassenberg S, Burmester G, van Riel P, Diaz-Lorente
M, Bruin GJ, et al: The human anti-IL-1 beta monoclonal antibody
ACZ885 is effective in joint inflammation models in mice and in a
proof-of-concept study in patients with rheumatoid arthritis.
Arthritis Res Ther. 10:R672008. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kalliolias GD and Liossis SN: The future
of the IL-1 receptor antagonist anakinra: From rheumatoid arthritis
to adult-onset Still's disease and systemic-onset juvenile
idiopathic arthritis. Expert Opin Investig Drugs. 17:349–359. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Settas LD, Tsimirikas G, Vosvotekas G,
Triantafyllidou E and Nicolaides P: Reactivation of pulmonary
tuberculosis in a patient with rheumatoid arthritis during
treatment with IL-1 receptor antagonists (anakinra). J Clin
Rheumatol. 13:219–220. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Botsios C, Sfriso P, Ostuni PA, Todesco S
and Punzi L: Efficacy of the IL-1 receptor antagonist, anakinra,
for the treatment of diffuse anterior scleritis in rheumatoid
arthritis. Report of two cases. Rheumatology (Oxford).
46:1042–1043. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nikfar S, Saiyarsarai P, Tigabu BM and
Abdollahi M: Efficacy and safety of interleukin-1 antagonists in
rheumatoid arthritis: A systematic review and meta-analysis.
Rheumatol Int. 38:1363–133. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Niu X, He D, Deng S, Li W, Xi Y, Xie C,
Jiang T, Zhang JZ, Dong C and Chen G: Regulatory immune responses
induced by IL-1 receptor antagonist in rheumatoid arthritis. Mol
Immunol. 49:290–296. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ohori M: ERK inhibitors as a potential new
therapy for rheumatoid arthritis. Drug News Perspect. 21:245–250.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Isomaki P, Junttila I, Vidqvist KL,
Korpela M and Silvennoinen O: The activity of JAK-STAT pathways in
rheumatoid arthritis: Constitutive activation of STAT3 correlates
with interleukin 6 levels. Rheumatology (Oxford). 54:1103–1113.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Boyle DL, Soma K, Hodge J, Kavanaugh A,
Mandel D, Mease P, Shurmur R, Singhal AK, Wei N and Rosengren S:
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT
signalling in rheumatoid arthritis. Ann Rheum Dis. 74:1311–1316.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Torices S, Julia A, Munoz P, Varela I,
Balsa A, Marsal S, Fernández-Nebro A, Blanco F, López-Hoyos M,
Martinez-Taboada V and Fernández-Luna JL: A functional variant of
TLR10 modifies the activity of NFkB and may help predict a worse
prognosis in patients with rheumatoid arthritis. Arthritis Res
Ther. 18:2212016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Trzybulska D, Olewicz-Gawlik A, Sikora J,
Frydrychowicz M, Kolecka-Bednarczyk A, Kaczmarek M and Hrycaj P:
The effect of caveolin-1 knockdown on interleukin-1β-induced
chemokine (C-C motif) ligand 2 expression in synovial fluid-derived
fibroblast-like synoviocytes from patients with rheumatoid
arthritis. Adv Clin Exp Med. 27:1491–1497. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yin G, Wang Y, Cen XM, Yang M, Liang Y and
Xie QB: Lipid peroxidation-mediated inflammation promotes cell
apoptosis through activation of NF-κB pathway in rheumatoid
arthritis synovial cells. Mediators Inflamm. 2015:4603102015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gordon RA, Grigoriev G, Lee A, Kalliolias
GD and Ivashkiv LB: The interferon signature and STAT1 expression
in rheumatoid arthritis synovial fluid macrophages are induced by
tumor necrosis factor alpha and counter-regulated by the synovial
fluid microenvironment. Arthritis Rheum. 64:3119–3128. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nakajima H, Takamori H, Hiyama Y and
Tsukada W: The effect of treatment with interferon-gamma on type II
collagen-induced arthritis. Clin Exp Immunol. 81:441–445. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Saha S, Qi J, Wang S, Wang M, Li X, Kim
YG, Núñez G, Gupta D and Dziarski R: PGLYRP-2 and Nod2 are both
required for peptidoglycan-induced arthritis and local
inflammation. Cell Host Microbe. 5:137–150. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Murray E, Ellis A, Butylkova Y, Skup M,
Kalabic J and Garg V: Systematic review and network meta-analysis:
Effect of biologics on radiographic progression in rheumatoid
arthritis. J Comp Eff Res. 7:959–974. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang QH, Lv SW, Guo YY, Duan JX, Dong SY,
Wang QS, Yu FM, Su H and Kuang HX: Pharmacological effect of
caulophyllum robustum on collagen-induced arthritis and regulation
of nitric oxide, NF-κB, and proinflammatory cytokines in vivo and
in vitro. Evid Based Complement Alternat Med. 2017:81343212017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ruscitti P, Cipriani P, Cantarini L,
Liakouli V, Vitale A, Carubbi F, Berardicurti O, Galeazzi M,
Valenti M and Giacomelli R: Efficacy of inhibition of IL-1 in
patients with rheumatoid arthritis and type 2 diabetes mellitus:
Two case reports and review of the literature. J Med Case Rep.
9:1232015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chabaud M, Page G and Miossec P: Enhancing
effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory
protein-3alpha production in rheumatoid arthritis: Regulation by
soluble receptors and Th2 cytokines. J Immunol. 167:6015–6020.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Takasugi K, Nishida K, Natsumeda M,
Yamashita M, Yamamoto W and Ezawa K: IL-6 is an independent
predictive factor of drug survival after dose escalation of
infliximab in patients with rheumatoid arthritis. Mod Rheumatol.
28:452–460. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yamana J, Yamamura M, Okamoto A, Aita T,
Iwahashi M, Sunahori K and Makino H: Resistance to IL-10 inhibition
of interferon gamma production and expression of suppressor of
cytokine signaling 1 in CD4+ T cells from patients with rheumatoid
arthritis. Arthritis Res Ther. 6:R567–R577. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sabry D, Elamir A, Mahmoud RH, Abdelaziz
AA and Fathy W: Role of LncRNA-AF085935, IL-10 and IL-17 in
rheumatoid arthritis patients with chronic Hepatitis C. J Clin Med
Res. 9:416–425. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Juhl P, Thudium CS, Gudmann NS, Karsdal
MA, Bay-Jensen AC and Siebuhr AS: IL-6 receptor inhibition
modulates type III collagen and C-reactive protein degradation in
rheumatoid arthritis patients with an inadequate response to
anti-tumour necrosis factor therapy: Analysis of connective tissue
turnover in the tocilizumab RADIATE study. Clin Exp Rheumatol.
36:568–574. 2018.PubMed/NCBI
|
|
42
|
Banko Z, Pozsgay J, Szili D, Tóth M, Gáti
T, Nagy G, Rojkovich B and Sármay G: Induction and differentiation
of IL-10-Producing regulatory B cells from healthy blood donors and
rheumatoid arthritis patients. J Immunol. 198:1512–1520. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ouyang BS, Che JL, Gao J, Zhang Y, Li J,
Yang HZ, Hu TY, Wu YJ and Yang M: Effects of electroacupuncture and
simple acupuncture on changes of IL-1, IL-4, IL-6 and IL-10 in
peripheral blood and joint fluid in patients with rheumatoid
arthritis. Zhongguo Zhen Jiu. 30:840–844. 2010.(In Chinese).
PubMed/NCBI
|
|
44
|
Li G, Xia Z, Liu Y, Meng F, Wu X, Fang Y,
Zhang C and Liu D: SIRT1 inhibits rheumatoid arthritis
fibroblast-like synoviocyte aggressiveness and inflammatory
response via suppressing NF-κB pathway. Biosci Rep.
38:BSR201805412018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Scheinman RI, Trivedi R, Vermillion S and
Kompella UB: Functionalized STAT1 siRNA nanoparticles regress
rheumatoid arthritis in a mouse model. Nanomedicine (Lond).
6:1669–1682. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Walker JG, Ahern MJ, Coleman M, Weedon H,
Papangelis V, Beroukas D, Roberts-Thomson PJ and Smith MD:
Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory
arthritis: Unique Jak3 and STAT4 expression in dendritic cells in
seropositive rheumatoid arthritis. Ann Rheum Dis. 65:149–156. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kasperkovitz PV, Verbeet NL, Smeets TJ,
van Rietschoten JG, Kraan MC, van der Pouw Kraan TC, Tak PP and
Verweij CL: Activation of the STAT1 pathway in rheumatoid
arthritis. Ann Rheum Dis. 63:233–239. 2004. View Article : Google Scholar : PubMed/NCBI
|
